Paul Hastings LLP, a leading global law firm, announced today that the firm represented UBS Securities LLC, J.P. Morgan Securities LLC, Jefferies Finance LLC, Keybank National Association and Morgan Stanley Senior Funding, Inc. as joint lead arrangers and joint bookrunners and UBS AG, Stamford Branch as administrative agent in connection with a $160 million and €70 million incremental add-on to DPx Holdings B.V.’s credit facility. The proceeds were used primarily for the purchase of Gallus BioPharmaceuticals, LLC, a contract manufacturing company involved in biologics development.
DPx Holdings B.V. is the privately held parent company of the Patheon, DPx Fine Chemicals and Banner Life Sciences businesses. The company is a leading provider of CDMO services, pharmaceutical products and products for other industries.
Leveraged Finance partners Michael Michetti and Joel Simon led the Paul Hastings team, which also included associates Chris Ross, Heidi Spalholz, Sun Kim, Mitch Zuckerman and Yian Huang.
In Thomson Reuters’ First Half 2014 League Table the firm ranked second in “U.S. Lender Law Firm Bookrunner M&A.” Paul Hastings advised on numerous significant finance transactions in the first half of 2014 including: representing the lenders in the $1.65 billion financing for the acquisition of a majority stake in Royal DSM NV’s pharmaceuticals business by JLL Partners (“JLL”) through Patheon Inc.; representing the lenders in the $1.3 billion financing of Apollo Global Management’s acquisition of CEC Entertainment, Inc.; advising the lenders in the $1.6 billion financing for Media General Inc.’s acquisition of Lin Media LLC; and representing the lenders in the $1.1 billion financing for Accellent Inc.’s acquisition of Lake Region Medical Inc.
Source: www.paulhastings.com
